AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04350307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 22-gauge needle
Description: 22-gauge Quincke needle used for epidural injection
Study NCT04350307 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25-gauge needle
Description: 25-gauge Quincke needle used for epidural injection
Study NCT02495454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga101
Study NCT00696969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B Deoxycholate
Description: 1 mg/kg e.o.d for 30 days
Study NCT00696969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambisome + Miltefosine
Description: Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
Study NCT00696969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambisome and Paromomycin
Description: Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
Study NCT02375191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study NCT02375191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT02596594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal nutrition port system
Description: Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
Study NCT01952756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: One tablet (100 mg) twice per day for 12 weeks
Study NCT01952756 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Placebo
Description: One tablet twice per day for 12 weeks
Study NCT02059850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Description: Given IV
Study NCT02059850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02059850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03967392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine
Description: TREATMENT
Study NCT00228917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib-MenAC
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b meningococcal AC-tetanus toxoid conjugate Vaccine
Study NCT00228917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hiberix
Description: Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine, Haemophilus influenzae type b conjugate vaccine
Study NCT03206190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrophysiology
Description: Electrophysiological tests will be used to characterize patients better.
Study NCT03206190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Testing functional performance
Description: By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
Study NCT03206190 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Non motor symptoms
Description: By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
Study NCT01835964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucose Variability Observation
Description: On the morning of \~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
Study NCT03232151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C-Arm Cone Beam Computed Tomography
Description: C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
Study NCT02279732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02279732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride injection, USP, or 5% dextrose injection
Study NCT02991456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rolapitant
Description: single 180 mg dose by mouth
Study NCT02991456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 8 mg by mouth daily
Study NCT01317914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary instruction
Description: Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
Study NCT04201275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC74647PA capsule
Description: Capsule administered orally once daily
Study NCT00696969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine and Paromomycin
Description: Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
Study NCT04107441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8 Part 1
Description: 5, 10, 20, and 40 mg AX-8 orally disintegrating tablets (ODTs), up to 80 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved on the back of the tongue while the subject is in a sitting position. The subjects will be instructed not to suck, chew or swallow the tablet, i.e. to allow it to dissolve on the back of the tongue without any further intervention.
Study NCT04107441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AX-8 Part 2
Description: 5 and 40 mg AX-8 orally disintegrating tablets (ODTs), 45 mg/day split over 2 time points, 8 hours apart (i.e. Dose 1: 0 hour and Dose 2: + 8 hours). AX-8 ODTs will be administered orally and will be dissolved in the mouth while the subject is in a sitting position. The subjects will be instructed to actively move the tablet around in their mouth (i.e. active oral manipulation of the tablet) until it is fully dissolved.
Study NCT02966470 — intervention group
Intervention type: DEVICE
Intervention: Obtain grip strength from a standardized gripometer
Description: Obtain grip strength from a standardized gripometer, 3 times on each hand
Study NCT04201275 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: HEC74647PA capsule matching placebo administered orally once daily
Study NCT05456061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% diquafosol eyedrops
Description: Diquas® (Santen, Osaka, Japan), six times per day.
Study NCT05456061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone punctal plug insertion
Description: a silicone punctal occluder (Parasol® Punctal Occluder, BVI, Waltham, Massachusetts, USA), inserted into the lower eyelid
Study NCT01537497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
Study NCT01537497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
Study NCT00321555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin
Description: LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% Sodium Chloride (NaCl) and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
Study NCT03507179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed denture
Description: construction of a 3d printed denture through a recent method instead of conventional processing
Study NCT03507179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional dentures
Description: conventional dentures
Study NCT04712032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG-guided bowel perfusion assessment
Description: ICG will be injected prior to anastomosis creation, to assess perfusion status of the bowel.
Study NCT03241810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seribantumab
Description: Seribantumab is a human monoclonal antibody that inhibits ErbB3 signalling
Study NCT03241810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant is an estrogen receptor antagonist with no agonist effects
Study NCT03241810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant is an estrogen receptor antagonist with no agonist effects
Study NCT03241810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03887611 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound diagnosis
Description: Ultrasound diagnosis of lesions with Samsung S-Detect and ECI technology
Study NCT00726505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, Once Daily, up to 29 days:
Study NCT02356874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
Study NCT06413888 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pancreaticoduodenectomy
Description: Surgical removal of the head of the pancreas, duodenum, extrahepatic bile duct, distal stomach, and proximal jejunum. Group A cohort will not have NGT placed in the postoperative period. Whereas, group B will have the NGT retained in the posoperative period
Study NCT02745756 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Progenitor Cell Transplant
Description: Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
Study NCT02745756 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH and Tumor Lysate Pulsed DC Vaccine
Description: Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
Study NCT02644382 — intervention group
Intervention type: OTHER
Intervention: qualitative data collection
Description: qualitative data collection
Study NCT00871715 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Description: A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
Study NCT00871715 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dose-Equivalent Usual & Customary Care - DEUCC
Description: Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
Study NCT00871715 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual and Customary Care - UCC
Description: Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
Study NCT02644382 — intervention group
Intervention type: OTHER
Intervention: survey
Description: survey pre and post-surgical consult
Study NCT02644382 — intervention group
Intervention type: OTHER
Intervention: decision aid
Description: web-based decision aid post-surgical consult
Study NCT01154751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SUPERA Interwoven self-expanding nitinol stent
Description: Insertion of stent at stenotic area
Study NCT01708668 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent epidural bolus
Study NCT04343118 — intervention group
Intervention type: PROCEDURE
Intervention: Hardware Removal
Description: elective removal of plate osteosynthesis at the clavicle
Study NCT03385330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LOWER oxygen saturation target group
Description: We will randomize infants with moderate or severe BPD to lower SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
Study NCT03385330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIGHER oxygen saturation target group
Description: We will randomize infants with moderate or severe BPD to higher SpO2 target ranges. The study team will then use novel technology to monitor infants starting at randomization, continuing after discharge and until 6 months corrected age, titrating supplemental oxygen to achieve these target SpO2 ranges.
Study NCT02622646 — intervention group
Intervention type: DRUG
Intervention: Recombinant VIII factor
Description: Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.~1. Describe PK parameters in patients on prophylaxis treatment with Advate®~2. Analyze differences in PK parameters in non-controlled vs well controlled patients~3. Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).~4. Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence).
Study NCT03005808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Surgery for appendicitis
Study NCT01462890 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
Study NCT01462890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 175 mg/m², iv on day 1 every 3 weeks for 6 cycles
Study NCT01462890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m², iv on day 1 every 3 weeks for 6 cycles
Study NCT01462890 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC 5, iv on day 1 every 3 weeks for 6 cycles
Study NCT01462890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5, iv on day 1 every 3 weeks for 6 cycles
Study NCT01462890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: specialized pathology review (Germany only)
Description: before randomization
Study NCT01462890 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specialized pathology review (Germany only)
Description: before randomization
Study NCT01024192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZOLPIDEM SL800750
Description: Pharmaceutical form: Zopidem 12.5 mg tablets~Route of administration: Oral~Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal system
Description: starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal system
Description: starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion
Description: 150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
Study NCT00086411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management
Description: Brief manual based therapy; four 15 minute session over 10 weeks.
Study NCT00086411 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Medication Management
Description: Brief manual based therapy; four 15 minute session over 10 weeks.
Study NCT00086411 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mayo Counseling
Description: Manual based therapy; Weekly 30 minute sessions for 10 weeks
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo patch
Description: placebo patch containing no nicotine
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo bupropion
Description: placebo pills
Study NCT00086411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo bupropion
Description: placebo pills
Study NCT04465812 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring and personalized feedback on smartphone app
Description: 1. Patients will record their blood pressure (once 1-week for patients with hypertension, every 3-month for those without), blood glucose (once 1-month for patients with diabetes), serum lipid metabolism (every 3-month for patients with dyslipidemia) on app, and medical staff will suggest continuing monitoring and recording or recommend outpatient visit;~2. Patients will complete Pittsburgh sleep quality index test on app every 3-month, and medical staff will contact with patients with index > 15 to assess detail clinical status and recommend outpatient visit if necessary;~3. Patients will complete Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) on app every 3-month, and medical staff will contact with patients with SAS>49 or SDS>52 to assess detail clinical status and recommend outpatient visit if necessary;~4. Patients will complete cognitive training games every week on app;~5. Medical staff will send health information on app
Study NCT00718770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Description: Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
Study NCT02162966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Colistin
Description: High Dose Colistin
Study NCT02162966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dose Colistin
Description: Standard Dose Colistin
Study NCT01624090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: 30 mcg/kg intravenous (IV) over 6 hours once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
Study NCT01954563 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
Study NCT01895309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enbrel (etanercept)
Study NCT01895309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB4 (proposed biosimilar to etanercept)